The BioPharm Brief: Billion-Dollar Bet, Smarter Immunotherapy, Hepatitis B Hope

May 29, 09:09 PM
Headliner
Share
Subscribe

Pfizer’s $10.5 billion oncology collaboration with Innovent, early clinical progress for a novel PD-1/IL-2 fusion protein, and promising Phase III hepatitis B cure data highlight today’s key developments in biopharmaceutical innovation.

Share
Subscribe
Next
The BioPharm Brief: Smarter Immunotherapy, Stronger Responses, Longer Survival
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief